Method of Screening Drug with the Use of 67 kDa Laminin Receptor and Drug Obtained Thereby

Abstract

It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step, of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, and angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic-effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.

1 - 30 . (canceled) 
   
   
       31 . A method of treating cancer, inhibiting cancer cell growth, or inhibiting cancer cell metastasis activity, comprising the step of providing to a subject a catechin which binds to a 67 kDa laminin receptor, wherein binding of said 67 kDa laminin receptor inhibits cancer cell growth or inhibits cancer metastasis activity of a cancer. 
   
   
       32 . The method of  claim 31  wherein said step of providing is performed orally. 
   
   
       33 . The method of  claim 31  wherein said catechin includes a galloyl group. 
   
   
       34 . The method of  claim 33  wherein said catechin is selected from (-)-epicatechin-3-O-gallate (ECG) and (-)-epigallocatechin-3-O-(3-O-methyl) gallate (EGCG″3Me). 
   
   
       35 . The method of  claim 31  wherein said catechin is (-)-epigallocatechin-3-O-gallate (EGCG). 
   
   
       36 . The method of  claim 31  wherein said catechin binds to said 67 kDa laminin receptor at a different locating from a laminin binding site where laminin binds to said 67 kDa laminin receptor. 
   
   
       37 . The method of  claim 31  wherein said cancer is a laminin receptor expression positive cancer. 
   
   
       38 . A method of inhibiting cancer cell growth, comprising the step of exposing cancer cells to a catechin which binds to a 67 kDa laminin receptor, wherein binding of said 67 kDa laminin receptor inhibits cell growth of said cancer cells, wherein said step of exposing is performed in vitro. 
   
   
       39 . A method of inhibiting cancer cell growth, comprising the step of exposing cancer cells to a catechin which binds to a 67 kDa laminin receptor, wherein binding of said 67 kDa laminin receptor inhibits cell growth of said cancer cells, wherein said step of exposing is performed in vivo.